drugset
drugset / Trial / NCT04298749

Safety and Tolerability of GX-P1 in Healthy Male Volunteers

NCT04298749 ↗

Phase 1 Completed 24 enrolled Genexine, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is a single-center, double-blind, placebo-controlled, phase I study with healthy male volunteers receiving ascending single dose of GX-P1

Timeline

Start
2020-08-11
Primary completion
2021-06-07
Completion
2021-06-07

Drugs

EvaluationDrugModalityDoseRoute
Subject GX-P1 Unknown — Intravenous

Indications

autoimmune disease